Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in the Treatment of Intermediate to High Risk Prostate Cancer

NCT03124433 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT03124433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03124433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in the Treatment of Intermediate to High Risk Prostate Cancer
Lead sponsor
Singapore General Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 20, 2017
Completion date
August 22, 2019
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate